This guidance will fully update the following:
 
Status In progress
Process STA Review
ID number 1013

Provisional Schedule

Expected publication July 2017

Project Team

Project lead Jenna Dilkes

Email enquiries

Consultees

Companies sponsors Roche Products (trastuzumab emtansine)
Others Department of Health
  NHS England
  Welsh Government
Patient carer groups Breast Cancer Now
Professional groups Association of Breast Surgery
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists
  UK Breast Cancer Group

Commentators

Comparator companies Actavis (vinorelbine) (Confidentiality agreement not signed, not participating)
  GlaxoSmithKline (lapatinib) (Confidentiality agreement not signed, not participating)
  Hospira UK (vinorelbine) (Confidentiality agreement not signed, not participating)
  Medac UK (vinorelbine) (Confidentiality agreement not signed, not participating)
  Pierre Fabre (vinorelbine) (Confidentiality agreement not signed, not participating)
  Roche Products (capecitabine) (Confidentiality agreement not signed, not participating)
  Wockhardt UK (vinorelbine) (Confidentiality agreement not signed, not participating)
Evidence review group School of Health and Related Research (ScHARR)
General commentators Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
09 May 2017 Committee meeting: 3
25 April 2017 Following receipt of additional analyses from the company, the CDF rapid reconsideration topic Trastuzumab emtansine for the treatment of locally advanced or metastatic HER2-positive breast cancer after treatment with trastuzumab and a taxane (review of TA371) will be discussed in committee on Tuesday 09 May 2017
01 February 2017 Committee meeting: 2
20 December 2016 - 20 January 2017 Appraisal consultation: 1
29 November 2016 Committee meeting: 1
12 July 2016 Invitation to participate

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance